MY209735A - Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereof - Google Patents
Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereofInfo
- Publication number
- MY209735A MY209735A MYPI2022002981A MYPI2022002981A MY209735A MY 209735 A MY209735 A MY 209735A MY PI2022002981 A MYPI2022002981 A MY PI2022002981A MY PI2022002981 A MYPI2022002981 A MY PI2022002981A MY 209735 A MY209735 A MY 209735A
- Authority
- MY
- Malaysia
- Prior art keywords
- crr
- exatecan
- cea antibody
- analog conjugate
- pharmaceutical use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
An anti-CEA antibody-exatecan analog conjugate and a pharmaceutical use thereof. Specifically, the anti-CEA antibody-exatecan analog conjugate is as shown in general formula (Pc-L-Y-D), wherein Pc is an anti-CEA antibody or an antigen-binding fragment thereof: L is a linker unit; Y is selected from -O-(CRR)-1CRR-C(O)-, -O-CRR-(CRR)-, -O-CRR-, -NH-(CRR)-CRR-C(O)-, and -S-(CRR)-CRR-C(O); and n is a decimal or integer from 1 to 10. (Formula)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911294912 | 2019-12-16 | ||
| PCT/CN2020/136396 WO2021121204A1 (en) | 2019-12-16 | 2020-12-15 | Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY209735A true MY209735A (en) | 2025-07-31 |
Family
ID=76478217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2022002981A MY209735A (en) | 2019-12-16 | 2020-12-15 | Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230055408A1 (en) |
| EP (1) | EP4079761A4 (en) |
| JP (1) | JP7827624B2 (en) |
| KR (1) | KR20220113747A (en) |
| CN (2) | CN118453897A (en) |
| AU (1) | AU2020410460A1 (en) |
| BR (1) | BR112022011632A2 (en) |
| CA (1) | CA3163130A1 (en) |
| MX (1) | MX2022007312A (en) |
| MY (1) | MY209735A (en) |
| TW (1) | TWI887316B (en) |
| UA (1) | UA129521C2 (en) |
| WO (1) | WO2021121204A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230101735A1 (en) * | 2020-01-22 | 2023-03-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof |
| JP7767613B2 (en) | 2021-11-15 | 2025-11-11 | システィミューン,インコーポレイテッド | Bispecific antibody-camptothecin drug conjugates and pharmaceutical uses thereof |
| EP4489862A1 (en) * | 2022-03-09 | 2025-01-15 | Merck Patent GmbH | Anti-ceacam5 antibodies and conjugates and uses thereof |
| AU2024380559A1 (en) | 2023-11-17 | 2026-06-04 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| KR20260115642A (en) | 2023-11-20 | 2026-07-24 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Method for producing heterogeneous multimers through recombination reaction |
| WO2026151884A1 (en) | 2025-01-09 | 2026-07-16 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2026158363A1 (en) * | 2025-01-22 | 2026-07-30 | 石药集团巨石生物制药有限公司 | Antibody-drug conjugate and use thereof |
| CN120504738B (en) * | 2025-07-21 | 2025-10-21 | 南京滴力生物科技有限公司 | Monoclonal antibody for resisting delta-like ligand 3 and application thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP1558284B1 (en) * | 2002-10-08 | 2013-09-11 | Immunomedics, Inc. | Combination therapy with naked class iii anti-cea monoclonal antibodies and therapeutic agents |
| ES2605443T3 (en) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| CN102850400A (en) * | 2011-06-30 | 2013-01-02 | 周文强 | Camptothecin derivative, and preparation method, pharmaceutical composition and use thereof |
| CN104168899B (en) | 2012-01-13 | 2017-04-05 | 通用医疗公司 | Anesthetic compounds and related methods of use |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| CN107753954A (en) * | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | The dosage of the antibody that effect is improved and toxicity reduces and SN 38 immunoconjugates |
| FR3008408B1 (en) * | 2013-07-11 | 2018-03-09 | Mc Saf | NOVEL ANTIBODY-MEDICAMENT CONJUGATES AND THEIR USE IN THERAPY |
| JP6427789B2 (en) * | 2013-07-23 | 2018-11-28 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | Antibody-SN-38 immune complex with CL2A linker |
| EP3066470A4 (en) * | 2013-11-05 | 2017-05-31 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| KR20190133233A (en) * | 2017-03-30 | 2019-12-02 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | How to prepare an antibody-drug conjugate |
| CA3044082A1 (en) * | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| TW202115125A (en) * | 2019-06-26 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Anti-cea antibody and the use thereof |
-
2020
- 2020-12-15 BR BR112022011632A patent/BR112022011632A2/en unknown
- 2020-12-15 MY MYPI2022002981A patent/MY209735A/en unknown
- 2020-12-15 JP JP2022535918A patent/JP7827624B2/en active Active
- 2020-12-15 WO PCT/CN2020/136396 patent/WO2021121204A1/en not_active Ceased
- 2020-12-15 CN CN202410472219.5A patent/CN118453897A/en active Pending
- 2020-12-15 US US17/785,373 patent/US20230055408A1/en active Pending
- 2020-12-15 MX MX2022007312A patent/MX2022007312A/en unknown
- 2020-12-15 CN CN202080078185.1A patent/CN114729035B/en active Active
- 2020-12-15 EP EP20902845.5A patent/EP4079761A4/en active Pending
- 2020-12-15 UA UAA202202371A patent/UA129521C2/en unknown
- 2020-12-15 CA CA3163130A patent/CA3163130A1/en active Pending
- 2020-12-15 KR KR1020227023180A patent/KR20220113747A/en active Pending
- 2020-12-15 AU AU2020410460A patent/AU2020410460A1/en active Pending
- 2020-12-16 TW TW109144510A patent/TWI887316B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI887316B (en) | 2025-06-21 |
| JP2023506805A (en) | 2023-02-20 |
| MX2022007312A (en) | 2022-07-13 |
| CN118453897A (en) | 2024-08-09 |
| KR20220113747A (en) | 2022-08-16 |
| US20230055408A1 (en) | 2023-02-23 |
| JP7827624B2 (en) | 2026-03-10 |
| BR112022011632A2 (en) | 2022-10-04 |
| CN114729035B (en) | 2024-04-16 |
| CA3163130A1 (en) | 2021-06-24 |
| CN114729035A (en) | 2022-07-08 |
| WO2021121204A1 (en) | 2021-06-24 |
| UA129521C2 (en) | 2025-05-21 |
| EP4079761A1 (en) | 2022-10-26 |
| TW202128228A (en) | 2021-08-01 |
| AU2020410460A1 (en) | 2022-06-16 |
| EP4079761A4 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008474A (en) | Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof. | |
| MX2022007312A (en) | ANTI-CEA-ANTIBODY-EACTONON ANALOGUE CONJUGATE AND MEDICAL USE THEREOF. | |
| BR112022011032A2 (en) | ANTI-CLAUDIN ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | |
| NO20083895L (en) | Anti-IGF-1R human monoclonal antibody formulation | |
| MX2023012456A (en) | Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal user thereof. | |
| CA3149406A1 (en) | Novel anti-cldn18.2 antibodies | |
| EP4005661A4 (en) | WHEEL ASSEMBLY, AND SOLID-LIQUID MIXING DEVICE USING THE SAME | |
| WO2022031884A3 (en) | Il2rg binding molecules and methods of use | |
| TW200510459A (en) | RG1 antibodies and uses thereof | |
| NZ597023A (en) | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same | |
| NZ724971A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
| NZ602166A (en) | Antibodies to il-6 and use thereof | |
| NO20053101L (en) | Chimeric and humanized antibodies motalfa-5beta-1 integrin that modulates angiogenesis. | |
| CU24648B1 (en) | DRUG CONJUGATES AND ANTI-CCR7 ANTIBODIES | |
| NZ616254A (en) | Complexes of il-15 and il-15ralpha and uses thereof | |
| NO20071436L (en) | Humanized Anti-5T4 Antibodies and Anti-5T4 Antibody / Calicheamicin Conjugates | |
| DK1383785T3 (en) | Recombinant tumor-specific antibody and its use | |
| MX2024007966A (en) | Novel anti-tslp antibodies. | |
| MX2020012679A (en) | Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof. | |
| NZ616382A (en) | Antibodies specific to cadherin-17 | |
| WO2022170280A3 (en) | Novel anti-cd24 antibodies | |
| AR082916A1 (en) | UNION MOLECULES AT 4-1BB | |
| NZ607711A (en) | Antibodies directed to her-3 and uses thereof | |
| MX2022007959A (en) | Novel anti-fgfr2b antibodies. | |
| NZ598594A (en) | Combinatorial therapy involving alpha5beta1 antagonists |